Total Payments
$246,695
2024 Payments
$877.78
Companies
50
Transactions
669
Medicare Patients
2,976
Medicare Billing
$386,132
Payment Breakdown by Category
Other$170,342 (69.0%)
Travel$39,141 (15.9%)
Research$23,791 (9.6%)
Food & Beverage$11,018 (4.5%)
Consulting$2,325 (0.9%)
Education$73.04 (0.0%)
Gifts$4.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $170,342 | 59 | 69.0% |
| Travel and Lodging | $39,141 | 57 | 15.9% |
| Unspecified | $23,791 | 9 | 9.6% |
| Food and Beverage | $11,018 | 536 | 4.5% |
| Consulting Fee | $2,325 | 1 | 0.9% |
| Education | $73.04 | 6 | 0.0% |
| Gift | $4.27 | 1 | 0.0% |
Payments by Type
General
$222,904
660 transactions
Research
$23,791
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $172,690 | 124 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $31,767 | 57 | $0 (2023) |
| Eli Lilly and Company | $23,791 | 9 | $0 (2020) |
| Takeda Pharmaceuticals America, Inc. | $11,018 | 25 | $0 (2017) |
| ABBVIE INC. | $1,638 | 94 | $0 (2024) |
| Janssen Biotech, Inc. | $1,160 | 89 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $700.72 | 46 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $393.65 | 22 | $0 (2024) |
| Allergan, Inc. | $295.92 | 29 | $0 (2020) |
| GENZYME CORPORATION | $284.17 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $877.78 | 39 | ABBVIE INC. ($159.00) |
| 2023 | $1,264 | 64 | ABBVIE INC. ($392.22) |
| 2022 | $1,024 | 59 | ABBVIE INC. ($204.65) |
| 2021 | $583.17 | 30 | Janssen Biotech, Inc. ($73.92) |
| 2020 | $7,630 | 23 | Janssen Scientific Affairs, LLC ($6,913) |
| 2019 | $66,223 | 146 | Janssen Scientific Affairs, LLC ($61,493) |
| 2018 | $105,694 | 178 | Janssen Scientific Affairs, LLC ($60,497) |
| 2017 | $63,399 | 130 | Janssen Scientific Affairs, LLC ($43,787) |
All Payment Transactions
669 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Immunology | ||||||
| 12/04/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug), PLENVU | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Gastroenterology | ||||||
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Immunology | ||||||
| 10/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.50 | General |
| Category: Neuroscience | ||||||
| 09/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.03 | General |
| 09/26/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Rare Disease | ||||||
| 09/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Gastroenterology | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Immunology | ||||||
| 08/30/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Immunology | ||||||
| 08/28/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: Immunology | ||||||
| 08/19/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $24.02 | General |
| Category: GI | ||||||
| 08/14/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 08/12/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/31/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.37 | General |
| Category: Neuroscience | ||||||
| 07/30/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $15,099 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $6,914 | 5 |
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $1,124 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $655.13 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 618 | 787 | $349,574 | $80,817 |
| 2022 | 14 | 599 | 784 | $329,623 | $79,019 |
| 2021 | 17 | 735 | 1,019 | $386,109 | $100,229 |
| 2020 | 17 | 1,024 | 1,292 | $495,383 | $126,068 |
Total Patients
2,976
Total Services
3,882
Medicare Billing
$386,132
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 128 | 210 | $57,750 | $19,422 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 190 | $38,000 | $12,263 | 32.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 78 | 78 | $66,300 | $11,961 | 18.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 97 | 106 | $68,900 | $9,387 | 13.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 35 | 35 | $27,700 | $6,408 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 48 | $16,800 | $6,194 | 36.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 15 | 16 | $19,424 | $3,468 | 17.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $9,600 | $2,941 | 30.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 15 | 15 | $12,050 | $2,814 | 23.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 34 | 34 | $10,200 | $2,426 | 23.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 18 | 18 | $14,400 | $2,245 | 15.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $8,450 | $1,287 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 361 | $99,275 | $32,022 | 32.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 63 | 63 | $53,550 | $9,077 | 17.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 69 | 73 | $47,450 | $6,404 | 13.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 29 | 29 | $22,900 | $5,335 | 23.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 34 | 34 | $27,100 | $4,853 | 17.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $11,200 | $4,447 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 26 | $9,100 | $3,171 | 34.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 14 | 14 | $16,996 | $2,892 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 40 | $8,000 | $2,698 | 33.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $9,300 | $2,152 | 23.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 30 | $5,252 | $1,712 | 32.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $10,700 | $1,534 | 14.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 27 | 44 | $4,400 | $1,376 | 31.3% |
About Mark Fleisher
Mark Fleisher is a Gastroenterology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134125891.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Fleisher has received a total of $246,695 in payments from pharmaceutical and medical device companies, with $877.78 received in 2024. These payments were reported across 669 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($170,342).
As a Medicare-enrolled provider, Fleisher has provided services to 2,976 Medicare beneficiaries, totaling 3,882 services with total Medicare billing of $386,132. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Jacksonville, FL
- Active Since 06/27/2005
- Last Updated 05/23/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1134125891
Products in Payments
- STELARA (Biological) $173,673
- Entyvio (Biological) $42,374
- LINZESS (Drug) $556.61
- Mavyret (Drug) $397.03
- XIFAXAN (Drug) $339.47
- DUPIXENT (Biological) $334.30
- ZEPOSIA (Drug) $268.52
- INJECTAFER (Drug) $248.47
- VIBERZI (Drug) $243.27
- SKYRIZI (Biological) $219.46
- Linzess (Drug) $205.83
- TRULANCE (Drug) $187.09
- XELJANZ (Drug) $185.68
- Creon (Drug) $174.26
- ZENPEP (Drug) $164.20
- Amitiza (Drug) $158.32
- REMICADE (Biological) $155.44
- DIFICID (Drug) $138.52
- Humira (Biological) $135.66
- RINVOQ (Biological) $131.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Jacksonville
Dr. Vivek Kumbhari, Md, MD
Gastroenterology — Payments: $370,572
Gastroenterology $370,572
Ali Moghani Lankarani, Md, MD
Gastroenterology — Payments: $141,025
Gastroenterology $141,025
Dr. Ryan Stidham, Md, MD
Gastroenterology — Payments: $125,236
Gastroenterology $125,236
Michael Wallace, Md, MD
Gastroenterology — Payments: $100,313
Gastroenterology $100,313
Ikechukwu Ibegbu, Md, MD
Gastroenterology — Payments: $97,596
Gastroenterology $97,596
Victoria Gomez, Md, MD
Gastroenterology — Payments: $79,939
Gastroenterology $79,939